| Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression S Lianoglou, V Garg, JL Yang, CS Leslie, C Mayr Genes & development 27 (21), 2380-2396, 2013 | 455 | 2013 |
| Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial AY Helena, AJ Schoenfeld, A Makhnin, R Kim, H Rizvi, D Tsui, C Falcon, ... JAMA oncology 6 (7), 1048-1054, 2020 | 120 | 2020 |
| Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS A Rose Brannon, G Jayakumaran, M Diosdado, J Patel, A Razumova, ... Nature Communications 12 (1), 3770, 2021 | 84 | 2021 |
| Affinity regression predicts the recognition code of nucleic acid–binding proteins R Pelossof, I Singh, JL Yang, MT Weirauch, TR Hughes, CS Leslie Nature biotechnology 33 (12), 1242-1249, 2015 | 54 | 2015 |
| TET2 guards against unchecked BATF3-induced CAR T cell expansion N Jain, Z Zhao, J Feucht, R Koche, A Iyer, A Dobrin, J Mansilla-Soto, ... Nature 615 (7951), 315-322, 2023 | 41 | 2023 |
| Cell‐free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience P Kothari, F Marass, JL Yang, CM Stewart, D Stephens, J Patel, M Hasan, ... Cancer medicine 9 (17), 6093-6101, 2020 | 38 | 2020 |
| Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients DWY Tsui, ML Cheng, M Shady, JL Yang, D Stephens, H Won, ... Genome medicine 13 (1), 96, 2021 | 28 | 2021 |
| CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis AJ Dunbar, D Kim, M Lu, M Farina, RL Bowman, JL Yang, Y Park, ... Blood, The Journal of the American Society of Hematology 141 (20), 2508-2519, 2023 | 18 | 2023 |
| Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS … AR Brannon, G Jayakumaran, M Diosdado, J Patel, A Razumova, Y Hu, ... bioRxiv, 2020.06. 27.175471, 2020 | 12 | 2020 |
| Jak2V617F reversible activation shows an essential requirement for Jak2V617F in myeloproliferative neoplasms (MPNs) A Dunbar, RL Bowman, Y Park, F Izzo, RM Myers, A Karzai, W Jun Kim, ... Blood 140 (Supplement 1), 803-804, 2022 | 7 | 2022 |
| Abstract LB153: Emergence of a hyper-proliferative phenotype in TET2 edited human CAR T cells N Jain, Z Zhao, A Iyer, M Lopez, J Feucht, R Koche, J Yang, Y Zhan, ... Cancer Research 81 (13_Supplement), LB153-LB153, 2021 | 4 | 2021 |
| Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms AJ Dunbar, RL Bowman, YC Park, K O'Connor, F Izzo, RM Myers, ... Cancer discovery, OF1-OF15, 2024 | 3 | 2024 |
| A lineage-specific epigenetic memory of inflammation potentiates Kras-driven pancreatic tumorigenesis DJ Falvo, A Grimont, P Zumbo, JL Yang, A Osterhoudt, SL Breves, G Pan, ... bioRxiv, 2021.11. 01.466807, 2021 | 3 | 2021 |
| A reversible epigenetic memory of inflammatory injury controls lineage plasticity and tumor initiation in the mouse pancreas DJ Falvo, A Grimont, P Zumbo, WB Fall, JL Yang, A Osterhoudt, G Pan, ... Developmental cell 58 (24), 2959-2973. e7, 2023 | 2 | 2023 |
| Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable T Codilupi, J Szybinski, S Arunasalam, S Jungius, AC Dunbar, S Stivala, ... Clinical Cancer Research 30 (3), 586-599, 2024 | | 2024 |
| Predicting tumour content of liquid biopsies from cell-free DNA M Cardner, F Marass, E Gedvilaite, JL Yang, DWY Tsui, N Beerenwinkel BMC bioinformatics 24 (1), 368, 2023 | | 2023 |
| AXL tyrosine kinase mediates escape from type II JAK2 inhibition in myeloproliferative neoplasms T Codilupi, J Szybinski, S Brkic, S Stivala, JL Yang, N Ghosh, JR Passweg, ... SWISS MEDICAL WEEKLY 152, 11S-11S, 2022 | | 2022 |
| Resistance to Type II JAK2 Inhibition via persistent MAPK Activation can be overcome by MEK Inhibition T Codilupi, J Szybinski, S Brkic, S Stivala, JL Yang, A Wicki, N Ghosh, ... ONCOLOGY RESEARCH AND TREATMENT 45 (SUPPL 2), 160-160, 2022 | | 2022 |
| Resistance to type II JAK2 inhibition in MPN is dependent on chromatin remodeling and MAPK activation and is targetable J Szybinski, T Codilupi, S Stivala, S Brkic, JL Yang, A Wicki, N Ghosh, ... SWISS MEDICAL WEEKLY 151, 12-12, 2021 | | 2021 |
| Therapeutic resistance to the novel JAK2 inhibitor CHZ868 in MPN is dependent on MEK-ERK activation and is targetable J Szybinski, T Codilupi, A Wicki, JL Yang, N Ghosh, J Passweg, D Tsakiris, ... SWISS MEDICAL WEEKLY, 10S-10S, 2020 | | 2020 |
Richard KocheMemorial Sloan Kettering CancerVerified email at mskcc.org
